Mountain Valley MD (TSE:MVMD)
:MVMD
Want to see TSE:MVMD full AI Analyst Report?
MVMD Stock Chart & Stats
C$0.02
<C$0.01(20.00%)
At close: 4:00 PM EST
C$0.02
<C$0.01(20.00%)
Day’s Range― - ―
52-Week RangeC$0.01 - C$0.11
Previous CloseN/A
Volume2.00K
Average Volume (3M)205.59K
Market Cap
C$24.66M
Enterprise ValueC$22.68M
Total Cash (Recent Filing)C$316.00K
Total Debt (Recent Filing)C$89.00K
Price to Earnings (P/E)―
Beta-0.81
Next Earnings
Jul 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding352,354,950
10 Day Avg. Volume152,980
30 Day Avg. Volume205,595
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)3.44
Price to Sales (P/S)177.77
P/FCF Ratio-2.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Minimal DebtEffectively zero reported debt materially lowers financial distress risk and preserves strategic optionality. Over a multi‑month horizon this reduces bankruptcy and interest burden risk, allowing management to allocate scarce cash to R&D or partnerships rather than debt service.
Platform Delivery Technologies & PartnershipsA platform focus on drug/vaccine delivery and wellness products can generate durable competitive advantages if core IP and partnerships scale. Platform economics and partner channels can amortize R&D cost and enable multiple commercial applications across pharma and consumer markets.
Positive Gross Profit Noted In 2025Transitioning to positive gross profit indicates product or segment unit economics can cover direct costs. Sustained positive gross margins create a runway to improve operating margins if operating expenses are controlled, supporting long‑term viability beyond transient revenue shocks.
Bears Say
Persistent Negative Operating Cash FlowConsistent multi‑year cash burn undermines self‑funding ability and forces reliance on external capital. Over months this raises dilution and execution risk, constrains investment in development/commercialization, and shortens runway absent financing or material revenue improvement.
Shrinking Equity BaseA materially eroded equity cushion reflects accumulated losses and weak capital resilience. This structural weakening reduces ability to absorb setbacks, increases probability and cost of future financings, and limits strategic flexibility over the medium term.
Very Small, Volatile Revenue And Deep LossesTiny and volatile top line with large recurring losses signals unproven product‑market fit and poor operating leverage. Without durable revenue growth, losses will persist, making sustainable margins and long‑term commercialization challenging absent clear revenue inflection or non‑dilutive funding.
Mountain Valley MD News
MVMD FAQ
What was Mountain Valley MD’s price range in the past 12 months?
Mountain Valley MD lowest stock price was C$0.01 and its highest was C$0.10 in the past 12 months.
What is Mountain Valley MD’s market cap?
Mountain Valley MD’s market cap is C$24.66M.
When is Mountain Valley MD’s upcoming earnings report date?
Mountain Valley MD’s upcoming earnings report date is Jul 09, 2026 which is in 72 days.
How were Mountain Valley MD’s earnings last quarter?
Mountain Valley MD released its earnings results on Mar 02, 2026. The company reported -C$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.002.
Is Mountain Valley MD overvalued?
According to Wall Street analysts Mountain Valley MD’s price is currently Overvalued.
Does Mountain Valley MD pay dividends?
Mountain Valley MD does not currently pay dividends.
What is Mountain Valley MD’s EPS estimate?
Mountain Valley MD’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mountain Valley MD have?
Mountain Valley MD has 352,354,950 shares outstanding.
What happened to Mountain Valley MD’s price movement after its last earnings report?
Mountain Valley MD reported an EPS of -C$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 33.333%.
Which hedge fund is a major shareholder of Mountain Valley MD?
Currently, no hedge funds are holding shares in TSE:MVMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mountain Valley MD
Mountain Valley MD Holdings Inc., through its subsidiary, Mountain Valley MD Inc., operates as a health and wellness company. The company engages in the implementation and licensing of its technologies to pharmaceutical, vaccine, and nutraceutical third parties. It offers Quicksome oral drug formulation and delivery technologies; Quicksol solubility formulation technology; and dose sparing adjuvant. In addition, the company is developing IM032 for the treatment of male beagle dogs for comparing intramuscular and subcutaneous dosing. Mountain Valley MD Holdings Inc. is headquartered in Concord, Canada.
Technical Analysis
Ayurcann Holdings Corp.
―
Revive Therapeutics
―
PharmaCielo
―
CanadaBis Capital
―
Lobe Sciences
―
Options Prices
Currently, No data available
---